Tag Archives: Jason Kolbert

Analysts Are Bullish on These Healthcare Stocks: Keryx Biopharma (KERX), Histogenics (HSGX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Keryx Biopharma (KERX – Research Report), Histogenics (HSGX – Research Report) and Kala Pharmaceuticals Inc (KALA – Research Report) with bullish sentiments.

Analysts Offer Insights on Healthcare Companies: ADMA Biologics (NASDAQ: ADMA) and Bellerophon (NASDAQ: BLPH)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ADMA Biologics (ADMA – Research Report) and Bellerophon (BLPH – Research Report) with bullish sentiments. ADMA Biologics (ADMA) H.C. Wainwright analyst Jason

Analysts Conflicted on These Healthcare Names: Can-Fite BioPharma (NYSE: CANF) and Acorda Therapeutics (NASDAQ: ACOR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Can-Fite BioPharma (NYSE:CANF) and Acorda Therapeutics (NASDAQ:ACOR). Can-Fite BioPharma (CANF) In a report released today, Jason Kolbert from H.C. Wainwright reiterated a Buy

H.C. Wainwright Reaffirms Their Buy Rating on Citius Pharmaceuticals Inc (CTXR)

In a report released today, Jason Kolbert from H.C. Wainwright reiterated a Buy rating on Citius Pharmaceuticals Inc (NASDAQ: CTXR), with a price target of $11. The company’s shares opened today at $1.51, close to its 52-week low of $1.12.

ADMA Biologics (ADMA) Initiated with a Buy at H.C. Wainwright

In a report released today, Jason Kolbert from H.C. Wainwright initiated coverage with a Buy rating on ADMA Biologics (NASDAQ: ADMA) and a price target of $17. The company’s shares closed yesterday at $5.03. Kolbert observed: “As noted, we believe

H.C. Wainwright Thinks Brainstorm Cell Therapeutics’ Stock is Going to Recover

H.C. Wainwright analyst Jason Kolbert maintained a Buy rating on Brainstorm Cell Therapeutics (NASDAQ: BCLI) today and set a price target of $11. The company’s shares opened today at $3.15, close to its 52-week low of $2.88. Kolbert wrote: “We